Dr. Peter Wrighton-Smith, a heavyweight in the life sciences industry, joins IonOpticks as Board Chair.

Dr Peter Wrighton-Smith’s journey began with a Masters in Engineering, Economics and Management, followed by a DPhil (PhD) in Medical Engineering, both from the University of Oxford. His career took off when he joined a startup developing a drug delivery device, sparking his interest in entrepreneurship and igniting his passion for scaling life science companies.

In 2002, Peter founded Oxford Immunotec, a leader in immunology-based diagnostics focused on improving the lives of millions affected by tuberculosis (TB), a major global health issue. Under his leadership as CEO from 2002 to 2022, Oxford Immunotec grew from a one-man operation in the attic of his rented home to a global NASDAQ-listed enterprise of 500 employees. With Peter at the helm, the company expanded to over 50 countries, established direct sales teams across the US, Europe, China, and Japan, and achieved revenues of $100 million. Oxford Immunotec was sold to Revvity in 2021 for $600 million.

In addition to his work at Oxford Immunotec, Peter has provided leadership to other life sciences companies, including Inivata, which was sold to NeoGenomics for $390 million in 2021. He currently serves as a Non-Executive Director of Mabtech, as well as a Non-Executive Director of NatCap, and Biomodal

Mårten Winge, an accomplished leader with extensive expertise in biotech and life sciences, joins IonOpticks’ Board of Directors.

Mårten’s academic foundation began with an MSc in Molecular Biology from the prestigious Karolinska Institute, laying the groundwork for a career defined by innovation and leadership in the life sciences industry. Over the past 25 years, Mårten has held multiple executive and board roles at several renowned companies, including Pyrosequencing, Olink, Halo Genomics, and Proxeon.

A seasoned executive with an international background in business management, Mårten’s experience spans business development, R&D, marketing, and commercialisation of new technologies across Europe, the USA, and Asia-Pacific. He has co-founded startups and successfully led several companies through key exits, such as Cartana’s acquisition by 10x Genomics, Halo Genomics’ acquisition by Agilent, and Proxeon’s acquisition by ThermoFisher.

Currently, Mårten serves on the boards of several organisations, including SwedenBio, Pelago Bioscience, and Countagen, a company he co-founded. His passion for fostering innovation and scaling growth aligns seamlessly with IonOpticks’ vision as the company continues to advance its position in the life sciences industry.

Sibel Arnes, a seasoned leader in healthcare and life sciences, joins IonOpticks’ Board of Directors. Sibel brings over a decade of expertise in the development and management of companies in these important sectors.

Sibel’s journey began at Bain & Company, where she supported companies across various industries with strategy and M&A. Her passion for healthcare and life sciences led her to Novo Holdings, where she spent six years investing into companies headquartered in Europe and the U.S. Throughout her career, Sibel has focused on investments ranging from $40 million to $2 billion, gaining deep insights into the complexities of global healthcare and life science subsectors. Her work across diverse markets has sharpened her strategic and operational expertise, making her a valuable asset in driving growth and innovation.

Since 2022 Sibel has been part of Adelis Equity Partners, where she helps lead the healthcare and life sciences investment efforts. Drawing on her past experiences, she brings a keen eye for value creation to the companies she oversees. Sibel’s board experience includes her current role at SSI Diagnostica Group and previous roles at BBI Solutions, Mission Bio, and Tempus AI.

Rasmus Molander, a seasoned leader in private equity and healthcare investments, joins IonOpticks’ Board of Directors.

Rasmus began his journey in the life sciences industry with a strong academic foundation, earning a MSc in Industrial Engineering and Biotechnology from the Helsinki University of Technology and a MBA from Harvard Business School. His early career saw him as an Investment Executive at Permira, a leading global private equity firm, where he specialised in healthcare. He also gained valuable experience as a consultant at the Boston Consulting Group (BCG).

In 2013 Rasmus joined Adelis Equity Partners, currently serving as co-managing partner, where he applies his expertise in healthcare investments and strategic growth to help businesses scale. He also holds extensive board experience across several companies, including SSI Diagnostica Group, Europa Biosite, Ropo, Puuilo, Re:mount, Valtti, QMG, and Med Group.
Rasmus is passionate about building businesses and helping them grow and internationalise, aligning with Adelis’ mission of investing in mid-sized firms and driving their expansion and development.

Xavier Perronnet is a visionary leader who projects a palpable enthusiasm for forging new paths in the worlds of property, finance, technology, and biotechnology. With a well-earned reputation for initiating, nurturing, and accelerating the growth of various ventures, his dynamic approach has consistently translated into successful market introductions of innovative products and services. At the helm of IonOpticks as its CEO, Xavier has harnessed his dedication for agile and strategic innovation, propelling the company into an exhilarating era characterised by rapid growth and robust international outreach.

His invaluable experience with startups and his adeptness at navigating the ever-shifting industry landscapes have been instrumental to IonOpticks’ triumphs. Xavier personifies exploration and tenacity, constantly seeking to expand the horizons of what can be achieved. He’s well-known for his exceptional ability to crystallise inventive concepts into tangible outcomes, fostering an environment where creativity and pragmatic action converge to drive progress. Under his guidance, IonOpticks doesn’t just adapt to change—it anticipates and shapes it.

Dr. Jarrod Sandow is not just the CPO at IonOpticks—he’s a driving force in the proteomics field. His dedication to innovation is shaping the future of how we understand human health. Leading a team of brilliant R&D scientists, Jarrod is focused on creating solutions that empower researchers and clinicians to dig deeper into their samples and fast-track discoveries in biology and medicine.

With a career spanning over 15 years in life sciences, Jarrod’s expertise has been crucial in delivering technologies that serve the global proteomics community. Before co-founding IonOpticks, he made significant strides as a senior researcher at the Walter and Eliza Hall Institute, working on a vast array of biomedical projects. He’s the kind of guy who’s as passionate about the minute details of product development as he is about the big picture of human health.